JTWM
SRPT icon

Jackson Thornton Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Jackson Thornton Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,476
Closed -$212K – 337
2025
Q4 		$212K Buy
+9,476
New +$200K 0.02% 289

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jackson Thornton Wealth Management's SRPT Position: Q1 2026 in Review

Jackson Thornton Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 9,476 shares — an estimated $212K sold.

Jackson Thornton Wealth Management first reported a position in SRPT in Q4 2025 and held it in 1 quarter. The position peaked at $212K in Q4 2025. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Jackson Thornton Wealth Management reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jackson Thornton Wealth Management sold 9,476 Sarepta Therapeutics shares in Q1 2026, an estimated $212K.
  • Jackson Thornton Wealth Management first reported a position in Sarepta Therapeutics in Q4 2025 and held it in 1 quarter.
  • Jackson Thornton Wealth Management's Sarepta Therapeutics position peaked at $212K in Q4 2025.
  • 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Jackson Thornton Wealth Management's 13F filing for Q1 2026, filed 29 Apr 2026.